scholarly journals Parkinson's Disease and Mesenchymal Stem Cells: Potential for Cell-Based Therapy

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Masaaki Kitada ◽  
Mari Dezawa
Keyword(s):  
Parkinson’S Disease ◽  
Stem Cells ◽  
Parkinson's Disease ◽  
Mesenchymal Stem Cells ◽  
Embryonic Stem ◽  
Dopamine Neurons ◽  
Technical Problems ◽  
Cell Based Therapy ◽  
Cell Source ◽  
Therapeutic Cell

Cell transplantation is a strategy with great potential for the treatment of Parkinson's disease, and many types of stem cells, including neural stem cells and embryonic stem cells, are considered candidates for transplantation therapy. Mesenchymal stem cells are a great therapeutic cell source because they are easy accessible and can be expanded from patients or donor mesenchymal tissues without posing serious ethical and technical problems. They have trophic effects for protecting damaged tissues as well as differentiation ability to generate a broad spectrum of cells, including dopamine neurons, which contribute to the replenishment of lost cells in Parkinson's disease. This paper focuses mainly on the potential of mesenchymal stem cells as a therapeutic cell source and discusses their potential clinical application in Parkinson's disease.

Stem cell-based therapy for Parkinson’s disease with a focus on human endometrium-derived mesenchymal stem cells

2018 ◽  
Vol 234 (2) ◽  
pp. 1326-1335 ◽  
Author(s):  
Saeid Bagheri-Mohammadi ◽  
Mohammad Karimian ◽  
Behrang Alani ◽  
Javad Verdi ◽  
Rana Moradian Tehrani ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Stem Cells ◽  
Parkinson's Disease ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Human Endometrium ◽  
Cell Based Therapy

scholarly journals Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease

Brain ◽  
2008 ◽  
Vol 131 (8) ◽  
pp. 2127-2139 ◽  
Author(s):  
Rosario Sanchez-Pernaute ◽  
Hyojin Lee ◽  
Michaela Patterson ◽  
Casper Reske-Nielsen ◽  
Takahito Yoshizaki ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Stem Cells ◽  
Parkinson's Disease ◽  
Embryonic Stem Cells ◽  
Embryonic Stem ◽  
Dopamine Neurons

scholarly journals Current Approaches and Molecular Mechanisms for Directly Reprogramming Fibroblasts Into Neurons and Dopamine Neurons

2021 ◽  
Vol 13 ◽  
Author(s):  
Fabin Han ◽  
Yanming Liu ◽  
Jin Huang ◽  
Xiaoping Zhang ◽  
Chuanfei Wei
Keyword(s):  
Parkinson’S Disease ◽  
Stem Cells ◽  
Parkinson's Disease ◽  
Immune System ◽  
Neural Stem Cells ◽  
Molecular Mechanisms ◽  
Embryonic Stem ◽  
Dopamine Neurons ◽  
Patient Specific ◽  
Direct Reprogramming

Parkinson’s disease is mainly caused by specific degeneration of dopaminergic neurons (DA neurons) in the substantia nigra of the middle brain. Over the past two decades, transplantation of neural stem cells (NSCs) from fetal brain-derived neural stem cells (fNSCs), human embryonic stem cells (hESCs), and induced pluripotent stem cells (iPSCs) has been shown to improve the symptoms of motor dysfunction in Parkinson’s disease (PD) animal models and PD patients significantly. However, there are ethical concerns with fNSCs and hESCs and there is an issue of rejection by the immune system, and the iPSCs may involve tumorigenicity caused by the integration of the transgenes. Recent studies have shown that somatic fibroblasts can be directly reprogrammed to NSCs, neurons, and specific dopamine neurons. Directly induced neurons (iN) or induced DA neurons (iDANs) from somatic fibroblasts have several advantages over iPSC cells. The neurons produced by direct transdifferentiation do not pass through a pluripotent state. Therefore, direct reprogramming can generate patient-specific cells, and it can overcome the safety problems of rejection by the immune system and teratoma formation related to hESCs and iPSCs. However, there are some critical issues such as the low efficiency of direct reprogramming, biological functions, and risks from the directly converted neurons, which hinder their clinical applications. Here, the recent progress in methods, mechanisms, and future challenges of directly reprogramming somatic fibroblasts into neurons or dopamine neurons were summarized to speed up the clinical translation of these directly converted neural cells to treat PD and other neurodegenerative diseases.

scholarly journals Recent advances in stem cell therapy for Parkinson’s Disease: A Review

2021 ◽  
pp. 34-39
Author(s):  
Mohammed Ashif ◽  
Nuseba Shehla Jeelani K ◽  
Vishnupriya J ◽  
Shripriya K ◽  
Muhamed Rinoob J
Keyword(s):  
Parkinson’S Disease ◽  
Stem Cells ◽  
Parkinson's Disease ◽  
Stem Cell ◽  
Embryonic Stem ◽  
Substantia Nigra Pars Compacta ◽  
Cell Based Therapy ◽  
Recent Advances ◽  
Long Term Treatment

Parkinson's disease (PD) is a degenerative neurological condition characterized by tremor, bradykinesia, and stiffness as cardinal motor characteristics. It's linked to a long-term loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc), resulting in a severe DA shortage in the striatum, which is necessary for motor function. There is presently no cure for Parkinson's disease, and the majority of treatments aimed at reversing dopamine depletion and alleviating symptoms. The transplantation of stem cells or stem cell derived progenitors has highlighted the potential of employing cell-based therapy to replace lost cells in the sick brain, based on promising findings from early experiments. Embryonic stem cells (ESCs) are highly expandable and pluripotent cells that can differentiate into any cell type in the human body, including nervous system tissues, suggesting that they could provide a long-term treatment for Parkinson's disease and other neurological illnesses. However, because of the potential for safety and ethical difficulties involved with the use of undifferentiated ESCs in people, other sources of transplantable cells must be considered. Another method is to use external manipulation to stimulate endogenous stem cells to heal the brain. Recent advances in stem cell research in Parkinson's disease will be discussed in this review, which will provide an overview of the various sources and strategies such as the use of different stem cell populations for cell replacement and possible modulation of endogenous stem cells, that have the potential to provide effective cell-based therapy in the future.

Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease

Nature ◽  
2002 ◽  
Vol 418 (6893) ◽  
pp. 50-56 ◽  
Author(s):  
Jong-Hoon Kim ◽  
Jonathan M. Auerbach ◽  
José A. Rodríguez-Gómez ◽  
Iván Velasco ◽  
Denise Gavin ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Stem Cells ◽  
Parkinson's Disease ◽  
Animal Model ◽  
Embryonic Stem Cells ◽  
Embryonic Stem ◽  
Dopamine Neurons

Intranasal administration of endometrial mesenchymal stem cells as a suitable approach for Parkinson’s disease therapy

2019 ◽  
Vol 46 (4) ◽  
pp. 4293-4302 ◽  
Author(s):  
Saeid Bagheri-Mohammadi ◽  
Behrang Alani ◽  
Mohammad Karimian ◽  
Rana Moradian-Tehrani ◽  
Mahdi Noureddini
Keyword(s):  
Parkinson’S Disease ◽  
Stem Cells ◽  
Parkinson's Disease ◽  
Mesenchymal Stem Cells ◽  
Intranasal Administration ◽  
Disease Therapy
Sign in / Sign up

Export Citation Format

Share Document